An important strategy in primary prevention of cardiovascular diseases (CVD) is the early identification of high-risk individuals. Effective implementation of a strategy to identify these individuals in a clinical setting is reliant on the availability of appropriate CVD risk-assessment models and guideline recommendations. Several well-known models for CVD risk assessment have been developed and utilized in the USA and Europe, but might not be suitable for use in other regions or countries. Very few reports have discussed the development of risk-assessment models and recommendations from a global perspective. In this Review, we discuss why risk-assessment methods developed from studies in one geographical region or ethnic population might not be suitable for other regions or populations, and examine the availability and characteristics of predictive models in areas beyond the USA or Europe. In addition, we compare the differences in risk-assessment recommendations outlined in CVD clinical guidelines from developed and developing countries, and consider their potential effect on clinical practice. This overview of cardiovascular risk assessment from a global perspective can potentially guide low-to-middle-income countries in the development or validation of their own CVD risk-assessment models, and the formulation of recommendations in their own clinical guidelines according to local requirements.
基金:
Clinical guidelines have an essential role in guiding clinical practice by providing physicians with recommendation based on the latest data. The first integrated clinical guidelines for CVD prevention that recommended total CVD risk assessment in clinical practice were developed and issued by the ESC, the European Atherosclerosis Society, and the European Society of Hypertension in 1994,62 which provided not only a risk-assessment chart and a definition of high risk based on equations developed from Framingham Heart Study data, but also total CVD risk-based clinical management strategies. The first set of clinical guidelines for the management of a single risk factor (dyslipidaemia) with a recommendation for total CHD risk assessment by risk charts was issued by the Scientific Committee of the National Heart Foundation of New Zealand in 1993.63 Most clinical guidelines for either a single risk factor or the integrated CVD risk factors that followed have recommended risk assessment as an central approach and a starting point for clinical management of CVD risk.5,64–87